Francisco Prieto-Ruiz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Francisco Prieto-Ruiz has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
- Armando Jesús Pérez-Díaz
Yeast Physiology Group. Department of Genetics and Microbiology. Campus de Excelencia Internacional de Ámbito Regional (CEIR) Campus Mare Nostrum, Universidad de Murcia
1 shared publication - María Ruso-López
Instituto de Biología Funcional y genómica, Universidad de Salamanca/CSIC, 37007 Salamanca, Spain
1 shared publication
Latest Publications
- Open Access
- 26 June 2026
- Published by MDPI AG in Precision Oncology
- Vol. 1 (3) , 10
Modulating the Actin Cytoskeleton to Regulate Autophagy and Overcome Chemotherapy Resistance in Tumours
Macroautophagy is a key adaptive process that enables tumour cells to withstand the cytotoxic stress induced by standard antitumour treatments, thereby contributing to therapeutic resistance. In this context, identifying regulators capable of modulating autophagy is crucial for restoring sensitivity to these treatments. The actin cytoskeleton has emerged as a regulatory axis of autophagy, governing both its dynamics and its functional control. Drugs that target actin, and in particular actin-binding proteins (ABPs), can modulate the autophagy triggered by antitumour treatments and thereby sensitise cancer cells. This review summarises recent advances in ABP-targeted strategies for modulating autophagy across different tumour contexts and examines their potential in combination therapies.
- 26 June 2026
- Published by MDPI AG in Precision Oncology
- Vol. 1 (3) , 10
Open AccessModulating the Actin Cytoskeleton to Regulate Autophagy and Overcome Chemotherapy Resistance in Tumours
Macroautophagy is a key adaptive process that enables tumour cells to withstand the cytotoxic stress induced by standard antitumour treatments, thereby contributing to therapeutic resistance. In this context, identifying regulators capable of modulating autophagy is crucial for restoring sensitivity to these treatments. The actin cytoskeleton has emerged as a regulatory axis of autophagy, governing both its dynamics and its functional control. Drugs that target actin, and in particular actin-binding proteins (ABPs), can modulate the autophagy triggered by antitumour treatments and thereby sensitise cancer cells. This review summarises recent advances in ABP-targeted strategies for modulating autophagy across different tumour contexts and examines their potential in combination therapies.